Maegim한국어

티디에스팜

464280KOSDAQSector: Pharma & Biotech
₩5,440▼ 1.27%Market cap ₩30.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A70.6 ptsTop 10% of 2,523 stocks
Financial strength
78.0
Growth momentum
40.4
Price attractiveness
83.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

78.0
How much debt does it carry relative to equity?
Debt-to-equity ratio
26.6%
✓ Above median · Top 26.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
266.1%
✓ Above median · Top 36.4% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
13.6%
✓ Above median · Top 13.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
10.0%
✓ Above median · Top 12% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

40.4
How much did revenue grow in a year?
Revenue growth (YoY)
0.4%
✗ Below median · Top 65.5% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
1.0%
✗ Below median · Top 53.8% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

83.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
7.0x
✓ Above median · Top 7.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.70x
✓ Above median · Top 24.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15